Investigator

Kunter Yuce

Hacettepe University

KYKunter Yuce
Papers(1)
Multi-institutional v…
Collaborators(10)
Melis GultekinOzan Cem GulerOzden AltundagSezin Yuce SariTeuta Zoto MustafayevYasemin BolukbasiZafer ArikAli AyhanBanu AtalarBerna Akkus Yildirim
Institutions(4)
Hacettepe UniversityBaskent ÜniversitesiUHNKoç Üniversitesi Tıp …

Papers

Multi-institutional validation of the ESMO-ESGO-ESTRO consensus conference risk grouping in Turkish endometrial cancer patients treated with comprehensive surgical staging

In this study, 683 patients with endometrial cancer (EC) after comprehensive surgical staging were classified into four risk groups as low (LR), intermediate (IR), high-intermediate (HIR) and high-risk (HR), according to the recent consensus risk grouping. Patients with disease confined to the uterus, ≥50% myometrial invasion (MI) and/or grade 3 histology were treated with vaginal brachytherapy (VBT). Patients with stage II disease, positive/close surgical margins or extra-uterine extension were treated with external beam radiotherapy (EBRT)±VBT. The median follow-up was 56 months. The overall survival (OS) was significantly different between LR and HR groups, and there was a trend between LR and HIR groups. Relapse-free survival (RFS) was significantly different between LR and HIR, LR and HR and IR and HR groups. There was no significant difference in OS and RFS rates between the HIR and HR groups. In HR patients, the OS and RFS rates were significantly higher in stage IB - grade 3 and stage II compared to stage III and non-endometrioid histology without any difference between the two uterine-confined stages and between stage III and non-endometrioid histology. The current risk grouping does not clearly discriminate the HIR and IR groups. In patients with comprehensive surgical staging, a further risk grouping is needed to distinguish the real HR group.Impact statement

1Papers
14Collaborators
Neoplasm Recurrence, LocalNeoplasm StagingDisease-Free SurvivalAdenocarcinoma, Clear CellUterine NeoplasmsCarcinoma, EndometrioidNeoplasm Invasiveness